

Sarah L Sammons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8421199/publications.pdf>

Version: 2024-02-01

23
papers

250
citations

1307594

7
h-index

996975

15
g-index

24
all docs

24
docs citations

24
times ranked

495
citing authors

#	ARTICLE	IF	CITATIONS
1	HR+, HER2-Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles. <i>Current Cancer Drug Targets</i> , 2017, 17, 637-649.	1.6	65
2	Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. <i>Neuro-Oncology</i> , 2017, 19, 1391-1397.	1.2	28
3	The Dysregulated Pharmacology of Clinically Relevant <i>ESR1</i> Mutants is Normalized by Ligand-activated WT Receptor. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1395-1405.	4.1	26
4	Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. <i>Clinical Breast Cancer</i> , 2018, 18, 410-417.	2.4	24
5	Copper suppression as cancer therapy: the rationale for copper chelating agents in <i>BRAF</i> ^{V600} mutated melanoma. <i>Melanoma Management</i> , 2016, 3, 207-216.	0.5	21
6	Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2- Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 1-11.	2.4	20
7	Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. <i>Targeted Oncology</i> , 2019, 14, 1-12.	3.6	12
8	Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data. <i>Clinical Breast Cancer</i> , 2021, 21, e340-e361.	2.4	10
9	Advances in the management of breast cancer brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, v63-v74.	0.7	10
10	The Promise of Immunotherapy for Breast Cancer Brain Metastases. <i>Current Breast Cancer Reports</i> , 2019, 11, 241-247.	1.0	7
11	Metastatic breast cancer: Who benefits from surgery?. <i>American Journal of Surgery</i> , 2022, 223, 81-93.	1.8	6
12	Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1091-1091.	1.6	5
13	Receptor discordance in breast cancer brain metastases: when knowledge is power. <i>Neuro-Oncology</i> , 2020, 22, 1060-1061.	1.2	3
14	The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease. <i>Drugs and Aging</i> , 2020, 37, 331-348.	2.7	3
15	The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease. <i>Drugs and Aging</i> , 2020, 37, 349-358.	2.7	3
16	Cardiotoxicities of Modern Treatments in Breast Cancer. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 34.	0.9	2
17	Abstract PS13-33: Feasibility of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with fam-trastuzumab deruxtecan. <i>Cancer Research</i> , 2021, 81, PS13-33-PS13-33.	0.9	2
18	Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 805-814.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Abstract PD14-09: APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD). Cancer Research, 2022, 82, PD14-09-PD14-09.	0.9	1
20	Impact of extracranial disease status on survival after initial central nervous system (CNS) involvement and radiation therapy in HER2+ breast cancer brain metastases (BCBM).. Journal of Clinical Oncology, 2021, 39, 1041-1041.	1.6	0
21	Immune Checkpoint Inhibition. , 2018, , 315-353.		0
22	Abstract P4-10-06: Best quality care from a distance (BQual-D): Maintaining high quality care for hormone receptor positive (HR+) metastatic breast cancer (MBC) during the COVID pandemic, description of the program and provider satisfaction. Cancer Research, 2022, 82, P4-10-06-P4-10-06.	0.9	0
23	Systemic management of brain metastases in HER2+ breast cancer in 2022.. Clinical Advances in Hematology and Oncology, 2022, 20, 325-336.	0.3	0